The Rivelin Plain Patch is developed as a CE marked product to be used as mechanical barrier occluding mucosal ulcers and inflammation.

The Rivelin Clobetasol Patch is developed for Oral Lichen Planus (OLP). A randomized, double-blind, placebo-controlled, parallel group, multiple centre study in EU and US will be launched in mid-2018. The aim is to assess the safety and efficacy of three doses of clobetasol and placebo when administered intra-orally twice daily in patients with painful OLP using the Rivelin clobetasol patch in a concentration of: 1 µg, 5 µg, and 20 µg per patch, dosed twice daily for two weeks with the option to dose for an additional two weeks. The dosing period will be followed by a two weeks follow up.